ProCE Banner Activity


Exploring the Latest Advances in Basal Cell Carcinoma

PCE On Demand Live Presentation

Patients with advanced basal cell carcinoma (BCC) now have multiple options for systemic therapy. In this activity, an advanced practice provider explains the mechanisms of action and optimal use of hedgehog pathway inhibitors and the immune checkpoint inhibitor cemiplimab. The case-based discussion illustrates treatment decision points and management of adverse events associated with these systemic therapies, with a focus on education of patients and caregivers.

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: December 29, 2022

Expiration: December 28, 2023

No longer available for credit.



Kathleen Madden

Kathleen Madden, MSN, ANP-BC, AOCNP

Melanoma Program
NYU Langone Perlmutter Cancer Center
New York, NY

Provided by

ProCE Banner


This activity is supported by educational grants from

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme

Target Audience

Oncology NPs, PAs, and nurses

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify the mechanisms via which novel therapies target the treatment of BCC

  • Describe evidence-based approaches for the treatment of advanced and metastatic BCC

  • Implement recommended approaches for the identification and management of treatment-related toxicities in BCC


All faculty and planners participating in continuing education activities sponsored by Partners for Advancing Clinical Education (PACE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PACE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Kathleen Madden, MSN: consultant/advisor/speaker: Novartis.

Anna Pavlick, MD, MBA: consultant/advisor/speaker: Bristol-Myers Squibb, Merck, Replimune.

The planners and content peer reviewers from Partners for Advancing Clinical Education and Practicing Clinicians Exchange, do not have any relevant financial relationships to disclose, except Anna Pavlick, MD, MBA, as noted above.

Instructions for Credit

Learners wishing to earn CE/CME credit must: 

  1. View the content in its entirety
  2. Relate the content material to the learning objectives 
  3. Complete evaluation form 

The estimated time to complete this activity is 1.00 hour.

Release date: December 29, 2022
Expiration date: December 28, 2023


This program has been made available online.


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Partners for Advancing Clinical Education, Practicing Clinicians Exchange, or any educational supporter.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team


ANCC Credit Designation
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit


AAPA Credit Designation
Joint AccreditationPartners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until December 28, 2023. PAs should only claim credit commensurate with the extent of their participation.

PA course advisor:  Jessica Garner, DMSc, PA-C


IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.